Atlas
Market PulseSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › GLAXO

GLAXO

GlaxoSmithKline Pharmaceuticals Limited
Mid-capHealthcare ↗

What the six lenses say about GLAXO — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹2440.4
2026-07-10
VWAP · 1Y anchor
₹2497
-2.3% from VWAP
P/E · TTM
39.9×
TTM EPS ₹61.1
52-week range
30%
position low→high
RSI(14)
65
momentum

Own sector index

Healthcare ↗
Overweight

1M

+5.5%

3M

+14.9%

1Y

+12.8%

Breadth >EMA21

68%

How GLAXO’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.0
avg conviction decile
Leadership
0/2
active lenses · Tech & Flow
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Mid-cap cohortDRaw
TechnicalD660›

The actual numbers

Price vs VWAP (1y)-2.3%
EMA trend stackMixed
Price vs 200-EMA+0.8%
Price vs 50-EMA+4.8%
RSI(14)65
RS vs Nifty 500 · 3M+1.2%
RS vs sector · 3M-10.3%
52-week range30%
Volume vs 30d avg0.17×
Volume vs 60d avg0.20×
ATR(14) · volatility59.1
Bollinger width · vol contraction0.178
FundamentalD762›

The actual numbers

Return on equity (ROE)45.6%
Return on capital (ROCE)61.4%
Operating margin36.9%
Net margin27.1%
Revenue growth · YoY+1.9%
EPS growth · YoY+12.2%
Debt / equity0.01×

Full 8-quarter history in the financials table below.

ValuationD734›

The actual numbers

P/E (TTM)39.9×
TTM EPS₹61.1
52-week range30%
CatalystD230›

The actual numbers

Earnings & momentum31
Capital actions5
Governance75

Every filing in the corporate-announcements panel below.

FlowD650›

The actual numbers

Promoter holding75.0%
Delivery · 30d avg58.1%
Up/down-day asymmetry-0.8pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Mid-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D6 + D6 ) ÷ 2 = 6.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · High
59
Conviction score 59/100 · avg-decile strength 6.0/10
Conviction score59/100›
TechnicalD6›
FundamentalD7›
ValuationD7›
CatalystD2›
FlowD6›

Policy

Government policy · Healthcare

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-07-10.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.9pp
+1.9pp
+9.0pp
+4.9pp
+12.2pp
-17.6pp
Nifty 500
Broad-market baseline
+0.5pp
+1.8pp
+8.4pp
+1.2pp
+7.1pp
-21.4pp
Sector
Own-sector index
—
—
+6.7pp
-10.3pp
-5.6pp
-35.9pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

GLAXO daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
2440.40+29.60

Relative strength

RS vs baseline · rebased to 100

GLAXO ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
98.97+0.46

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)8151,0119499748059801,041995
↳ change QoQ—+24.1%-6.1%+2.6%-17.4%+21.7%+6.2%-4.4%
EBITDA (₹cr)266361327333251336371351
EBITDA margin32.7%35.7%34.4%34.2%31.2%34.3%35.6%35.3%
PAT (₹cr)182253230263205257296278
↳ change QoQ—+38.5%-9.0%+14.4%-22.1%+25.4%+15.2%-6.1%
Net margin22.4%25.0%24.2%27.0%25.5%26.2%28.4%27.9%
EPS (₹)10.7614.6713.5715.5212.1015.2017.4516.40
D/E————————
YoY growth · Mar '26Revenue +2.2% YoYPAT +5.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 8 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 5 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMgovernance
    Resignation of Director/KMP/SMP
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 29 May '26
    MEDIUMgovernance
    Cessation
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 May '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 13 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗
  • 7 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Apr '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Apr '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Mar '26
    LOWgovernance
    Action(s) initiated or orders passed
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 24 Mar '26
    LOWgovernance
    Action(s) initiated or orders passed
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds GLAXO

Mutual funds holding GLAXO (10)

FundWeightAUM ₹crGrade
Kotak Large & Midcap Reg Gr0.86%31,263
SBI Midcap Reg Gr1.22%24,127
Nippon India Pharma Bns2.47%9,044
Nippon India Pharma Gr2.47%9,044
ICICI Pru Smallcap Instl Gr0.55%8,949
ICICI Pru Smallcap Gr0.55%8,949
Bajaj Finserv Flexi Cap Reg Gr1.06%7,195
Aditya BSL Multi-Cap Reg Gr0.73%6,811
Bandhan ELSS Tax saver Reg Gr0.83%6,767
Bandhan Multi Cap Reg Gr0.87%2,919

ETFs holding GLAXO (2)

ETFWeightGrade
Mirae Asset Nifty 500 Healthcare ETF0.73%
Motilal Oswal BSE Healthcare ETF0.61%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Healthcare